Veronica Ridpath
Psychiatry · Florence, SCNPI 1851825780
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $246,426 of the $364,081 with a category attached, or 67.7%. 21 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 40.1% of the total. 2025 is the largest year on record at $253,355, more than ten times the $164 reported in 2021. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $624.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$146K
- Neurocrine Biosciences, Inc.$71K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48K
- Alkermes, Inc.$45K
- Teva Pharmaceuticals USA, Inc.$29K
- AbbVie$16K
- plus $9K from 15 others
Across 1 payment — averaging $3300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
What the payments were for
- Consulting fees$80,54922%
- Speaking & faculty fees$246,42668%
- Travel & lodging$24,1987%
- Food & beverage$12,7233%
- Education$1850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 152 | $145,856 |
| Neurocrine Biosciences, Inc. | 101 | $71,267 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $48,165 |
| Alkermes, Inc. | 79 | $44,724 |
| Teva Pharmaceuticals USA, Inc. | 58 | $29,076 |
| AbbVie | 44 | $15,890 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $7,503 |
| Johnson & Johnson | 21 | $416 |
| Otsuka America Pharmaceutical, Inc. | 15 | $270 |
| E.r. Squibb & Sons, L.L.C. | 9 | $223 |
| Indivior Inc. | 11 | $163 |
| Vanda Pharmaceuticals Inc. | 6 | $100 |
| Supernus Pharmaceuticals, Inc. | 5 | $92 |
| Sage Therapeutics, LLC | 3 | $78 |
| Corium, LLC | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 4 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
| Lundbeck LLC | 2 | $33 |
| Tris Pharma Inc | 1 | $20 |
| Bausch Health US, LLC | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$364,081 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 42 | $312,771 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $57,355 |
| VraylarCariprazine Hcl | 31 | $44,085 |
| CaplytaLumateperone Tosylate | 22 | $38,742 |
| RexultiBrexpiprazole | 11 | $29,480 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $22,421 |
| Lurasidone Hcl | 36 | $20,013 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,622 |
| BelsomraSuvorexant | 19 | $15,751 |
| Quetiapine Fumarate | 137 | $2,258 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $1,943 |
| Vilazodone Hcl | 14 | $1,364 |
| Mirtazapine | 68 | $1,234 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $1,040 |
| Hydroxyzine Hcl | 65 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $29,076 | $312,77142 claims |
| Alkermes, Inc.Lybalvi | $44,724 | $57,35528 claims |
| AbbVieVraylar | $15,890 | $44,08531 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $48,165 | $38,74222 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $270 | $29,48011 claims |
| Axsome Therapeutics, Inc.Auvelity | $145,856 | $22,42127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Florence
- Nikunjkumar ModiFlorence$133K
- Brittany AlbrightMount Pleasant$691K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
- Floyd SalleeCharleston$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.